REGENERON PHARMACEUTICALS, INC. Recognition of Deferred Revenue
REGENERON PHARMACEUTICALS, INC. (REGN) reported Recognition of Deferred Revenue of $4.80 million for the 9-month period ending 2010-09-30, per its 10-Q filed 2011-10-27.
Discontinued › Income Statement › Other Income
us-gaap:RecognitionOfDeferredRevenue · last filed 2011-10-27
- REGENERON PHARMACEUTICALS, INC. recognition of deferred revenue for the quarter ending 2010-09-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. recognition of deferred revenue for the quarter ending 2010-06-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. recognition of deferred revenue for the quarter ending 2010-03-31 was $4.80M.
| Period end | Recognition of Deferred Revenue 3 month | Recognition of Deferred Revenue 6 month | Recognition of Deferred Revenue 9 month |
|---|---|---|---|
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $0.00 derived: sum of 2 quarters · filed 2011-10-27 | $4.80M 10-Q · filed 2011-10-27 |
| 2010-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $4.80M 10-Q · filed 2011-07-28 | |
| 2010-03-31 | $4.80M 10-Q · filed 2011-10-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |